CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lipidor AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lipidor AB
Svardvagen 13
DANDERYD, 182 33  Sweden Ticker: LIPILIPI

Business Summary
Lipidor AB is a Sweden-based drug delivery company focusing on topical medication. The Company is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The Company develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The Company’s cooperation partners include Cerbios-Pharma, which specializes in the development and manufacturing of chemical and biological active pharmaceutical ingredients (APIs), and Aurena Laboratories AB, a manufacturer of bag-on-valve aerosol sprays for the pharmaceutical and medical device industry.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2020Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board OlaFlink 78 1/1/2017 1/1/2017
Chief Executive Officer OlaHolmlund 50 1/1/2018
Chief Financial Officer MichaelOwens 66 1/1/2018
5 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 28,976,863 (As of 12/31/2023)
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024